Francesco Cocchiara1,2, Claudia Campana1, Federica Nista1, Giuliana Corica1, Marco Ceraudo3, Angelo Milioto1, Diego Criminelli Rossi3, Gianluigi Zona3, Diego Ferone1,2, Federico Gatto4. 1. Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI) and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy. 2. Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genoa, Italy. 3. Neurosurgery Unit, Department of Neurosciences (DINOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy. 4. Endocrinology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, 16132, Genoa, Italy. fedgatto@hotmail.it.
Abstract
PURPOSE: Acromegaly is a severe chronic endocrine disease. Achieving biochemical control often needs a multimodal treatment approach, including prolonged medical treatment. Aim of the study is to evaluate the burden of treatment direct costs with respect to the different therapeutic strategies, disease control, and follow-up length. METHODS: Single center retrospective study on 73 acromegaly patients. Costs of acromegaly treatments were computed based on a detailed revision of patients' clinical charts. RESULTS: Median total treatment cost/patient was €47,343 during the entire follow-up (8 years), while median treatment cost/patient/year was €6811. The majority of patients received medical therapy (71/73, 97.3%). Median cost for first-line medical treatment (first-generation somatostatin receptor ligands) was lower compared to second-line treatments (pegvisomant monotherapy or combination therapies), considering both total (€22,824 vs €76,140; p < 0.001), and yearly cost/patient (€4927 vs €9161; p < 0.001). Sixty patients (82.2%) reached biochemical control at last follow-up (IGF-1 ≤ 1 xULN). The percentage of patients treated with first- or second-line medical therapies was comparable between controlled and uncontrolled patients (p = 1.000), and the yearly cost/patient did not significantly differ between the two groups (€6936 vs €6680; p = 0.829). Follow-up duration was significantly longer in controlled patients compared to the uncontrolled ones (8.7 vs 3.5 years; p = 0.019). CONCLUSIONS: Direct costs for the management of acromegaly have a significant burden on the healthcare systems. However, more than 80% of our patients reached biochemical control using multimodal approaches. Treatment modalities and yearly costs did not significantly differ between controlled and uncontrolled patients, while follow-up length represented a major determinant of biochemical outcome.
PURPOSE: Acromegaly is a severe chronic endocrine disease. Achieving biochemical control often needs a multimodal treatment approach, including prolonged medical treatment. Aim of the study is to evaluate the burden of treatment direct costs with respect to the different therapeutic strategies, disease control, and follow-up length. METHODS: Single center retrospective study on 73 acromegaly patients. Costs of acromegaly treatments were computed based on a detailed revision of patients' clinical charts. RESULTS: Median total treatment cost/patient was €47,343 during the entire follow-up (8 years), while median treatment cost/patient/year was €6811. The majority of patients received medical therapy (71/73, 97.3%). Median cost for first-line medical treatment (first-generation somatostatin receptor ligands) was lower compared to second-line treatments (pegvisomant monotherapy or combination therapies), considering both total (€22,824 vs €76,140; p < 0.001), and yearly cost/patient (€4927 vs €9161; p < 0.001). Sixty patients (82.2%) reached biochemical control at last follow-up (IGF-1 ≤ 1 xULN). The percentage of patients treated with first- or second-line medical therapies was comparable between controlled and uncontrolled patients (p = 1.000), and the yearly cost/patient did not significantly differ between the two groups (€6936 vs €6680; p = 0.829). Follow-up duration was significantly longer in controlled patients compared to the uncontrolled ones (8.7 vs 3.5 years; p = 0.019). CONCLUSIONS: Direct costs for the management of acromegaly have a significant burden on the healthcare systems. However, more than 80% of our patients reached biochemical control using multimodal approaches. Treatment modalities and yearly costs did not significantly differ between controlled and uncontrolled patients, while follow-up length represented a major determinant of biochemical outcome.
Authors: M Caputo; A Ucciero; C Mele; L De Marchi; C Magnani; T Cena; P Marzullo; F Barone-Adesi; G Aimaretti Journal: J Endocrinol Invest Date: 2018-08-01 Impact factor: 4.256
Authors: Rudolf Fahlbusch; David Kleinberg; Beverly Biller; Vivien Bonert; Michael Buchfelder; Paolo Cappabianca; John Carmichael; William Chandler; Annamaria Colao; Ajax George; Anne Klibanski; Edmond Knopp; Juergen Kreutzer; Neehar Kundurti; Martin Lesser; Adam Mamelak; Rosario Pivonello; Kalmon Post; Brooke Swearingen; Mary Lee Vance; Ariel Barkan Journal: Pituitary Date: 2017-12 Impact factor: 4.107
Authors: Abd Moain Abu Dabrh; Khaled Mohammed; Noor Asi; Wigdan H Farah; Zhen Wang; Magdoleen H Farah; Larry J Prokop; Laurence Katznelson; Mohammad Hassan Murad Journal: J Clin Endocrinol Metab Date: 2014-10-30 Impact factor: 5.958
Authors: Jakob Dal; Ulla Feldt-Rasmussen; Marianne Andersen; Lars Ø Kristensen; Peter Laurberg; Lars Pedersen; Olaf M Dekkers; Henrik Toft Sørensen; Jens Otto L Jørgensen Journal: Eur J Endocrinol Date: 2016-06-08 Impact factor: 6.664